One of the biggest challenges in treating Alzheimer’s disease (AD) is how heterogeneous it is in terms of speed of decline and presence of other pathologies. That is, more than 50% of people with AD have other pathologies that influence how fast or slow cognitive decline will be.
Continue Reading this article here
